Regenxbio Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -202.9% | – | – | -194.8% | – | – | – | |
| – | +0.0% | +580.0% | +393.8% | +48.3% | +79.6% | +17.5% | +13.8% | +35.0% | +34.2% | -6.4% | -3.7% | |
| – | +815.7% | +140.7% | +50.8% | +56.9% | +61.4% | +19.0% | +21.5% | +5.1% | -1.3% | -4.5% | -10.1% | |
| – | +559.1% | +165.2% | +34.3% | +43.7% | +26.9% | +91.9% | +1.7% | +11.4% | – | – | – | |
| – | -373.9% | – | -82.8% | -966.7% | – | – | +182.8% | -65.2% | -177.9% | – | +112.9% | |
| – | +0.0% | +1,461.1% | -12.1% | +85.4% | -11.7% | +129.3% | +213.3% | -63.5% | -67.6% | -75.5% | -0.9% | |
| – | +0.0% | – | -125.0% | +5,732.1% | – | +31.2% | -431.3% | -97.1% | – | -45.8% | -115.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +23,930,900.0% | -99.9% | +210.6% | +52.3% | +55.1% | +36.9% | -100.1% | +14,100.0% | +47.5% | – | -12.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +9,867.1% | -100.0% | +70,990.8% | +141.7% | -95.9% | +2,290.3% | -2.5% | -114.8% | +21.2% | – | +26.0% | |
| – | +2,649,650.0% | -155.2% | – | +36.3% | -119.4% | – | -97.2% | -3,417.6% | – | – | -200.2% | |
| – | – | – | – | – | -230.7% | – | – | -276.8% | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.